Truffle Capital, an investor in Theraclion, is a European private equity firm originally set up for investments in spin-offs from companies active in the IT, Energy, and Life Sciences sectors.
-
Theraclion S.A.S., set up in 2004 as a spin-off from French EDAP-Technomed, is a medical device company developing novel applications of HIFU (High Intensity Focused Ultrasound) for the non-invasive treatment of thyroid and parathyroid disorders.
-
The company is addressing a potential market of one million new cases, conservatively valued at €300 million. with significant unmet needs for minimally invasive alternatives to surgery and no late stage competition.
-
The Theraclion device technology is now validated with proof of concept and preliminary phase 1 results available. Following a €4.1 million investment by Truffle Venture, Theraclion is pursuing its international technical and clinical development.
-
Truffle Capital board members: Philippe Pouletty, M.D. and CEO circle member Jacques Essinger